WO2009126444A3 - Compositions for the treatment of neurodegenerative conditions and methods for the use thereof - Google Patents

Compositions for the treatment of neurodegenerative conditions and methods for the use thereof Download PDF

Info

Publication number
WO2009126444A3
WO2009126444A3 PCT/US2009/038298 US2009038298W WO2009126444A3 WO 2009126444 A3 WO2009126444 A3 WO 2009126444A3 US 2009038298 W US2009038298 W US 2009038298W WO 2009126444 A3 WO2009126444 A3 WO 2009126444A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
methods
neurodegenerative conditions
disease
Prior art date
Application number
PCT/US2009/038298
Other languages
French (fr)
Other versions
WO2009126444A2 (en
Inventor
Michael D. Pierschbacher
Original Assignee
Alsp American Life Science Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alsp American Life Science Pharmaceuticals, Inc. filed Critical Alsp American Life Science Pharmaceuticals, Inc.
Publication of WO2009126444A2 publication Critical patent/WO2009126444A2/en
Publication of WO2009126444A3 publication Critical patent/WO2009126444A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is related to compositions useful for the treatment of subjects suffering from, or at risk of developing, a neurodegenerative condition such as Alzheimer's disease. Also provided are unit dosage forms of invention composions, as well as kits comprising invention compositions. Invention compositions are useful for a variety of applications, e.g., for the treatment of neurodegenerative conditions (such as, for example, Parkinson's disease, Alzheimer's disease, stroke and trauma), and the like.
PCT/US2009/038298 2008-04-09 2009-03-25 Compositions for the treatment of neurodegenerative conditions and methods for the use thereof WO2009126444A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4369908P 2008-04-09 2008-04-09
US61/043,699 2008-04-09

Publications (2)

Publication Number Publication Date
WO2009126444A2 WO2009126444A2 (en) 2009-10-15
WO2009126444A3 true WO2009126444A3 (en) 2010-02-18

Family

ID=41162504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/038298 WO2009126444A2 (en) 2008-04-09 2009-03-25 Compositions for the treatment of neurodegenerative conditions and methods for the use thereof

Country Status (1)

Country Link
WO (1) WO2009126444A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARRETT ET AL.: "L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L.", BIOCHEM. J., vol. 201, 1982, pages 189 - 198 *
GONZALEZ-PERIZ ET AL.: "Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA.", THE FASEB JOURNAL, vol. 20, 2006, pages E1844 - 1855 *

Also Published As

Publication number Publication date
WO2009126444A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
MX2009012950A (en) Humanized antibodies to aãŸ(20-42) globulomer and uses thereof.
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
UA99524C2 (en) Triazole derivatives useful for the treatment of diseases
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2006119170A3 (en) Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
WO2010059241A3 (en) Treatment of amyotrophic lateral sclerosis
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
EA200971050A1 (en) METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
MX2009003981A (en) Calcium receptor modulating agents.
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007017511A3 (en) Compounds for treating alzheimer's disease
WO2008057575A3 (en) Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
WO2008135661A3 (en) Use of citrulline for the treatment of conditions linked to an increase in protein carbonylation
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09730071

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09730071

Country of ref document: EP

Kind code of ref document: A2